SEC Form 4 · accession 0001852880-26-000002
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Everett Rand Sutherland
Director
Period of report
Sep 14, 2026
Accepted (ET)
Sep 16, 2026 · 8:03 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001711279
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $340.03 | Sep 14, 2026 | A | 1,187 | A | — | Sep 13, 2036 | Common Stock | 1,187 | 1,187 | D |
| Restricted Stock UnitsF2,F3 | — | Sep 14, 2026 | A | 471 | A | — | — | Common Stock | 471 | 471 | D |
Explanation of responses
- F1The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
- F2Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- F3The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.